Medicskin Holdings Ltd. (8307) AI Stock Analysis

• Market Cap: HK$73.79M
• Dividend Yield: N/A
• Average Volume (3M): 347.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: -8.20%
• EPS Growth: -10.39%
• Country: HK
• Employees: 29
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Care Facilities
• EPS (TTM): >-0.01
• Shares Outstanding: 396,736,000
• 10 Day Avg. Volume: 8,000
• 30 Day Avg. Volume: 347,600
• PEG Ratio: N/A
• Price to Book (P/B): 15.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 5.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: HK$0.00 ▼(-100.00%Downside)

Medicskin Holdings Ltd. has a challenging financial position with high leverage and negative profitability impacting its overall score. Despite technical indicators showing a positive trend, the valuation remains unattractive due to negative earnings. Strong cash flow management provides some stability. Improvement in profitability and leverage could enhance the stock's prospects.

Medicskin Holdings Ltd. Business Overview & Revenue Model

Company Description

Medicskin Holdings Ltd. (8307) is a Hong Kong-based investment holding company primarily involved in the provision of skin care services. The company offers a range of aesthetic treatments, including medical skincare solutions, laser treatments, and other beauty and wellness services. Medicskin operates through its network of service centers, aiming to cater to the beauty and healthcare needs of its clients with advanced technology and personalized care.

How the Company Makes Money

Medicskin Holdings Ltd. generates revenue primarily through its skin care service offerings. The company charges clients for various treatments and procedures conducted at its service centers, such as laser therapies, skincare consultations, and aesthetic enhancements. Medicskin leverages its expertise in dermatology and aesthetic medicine to attract a diverse clientele seeking professional skin care solutions. Additionally, the company may earn income from product sales related to its treatments, such as skincare products recommended post-treatment. Strategic partnerships with medical professionals and suppliers of advanced skincare technology also play a role in enabling the company to maintain a competitive edge and drive revenue.

Medicskin Holdings Ltd. Financial Statement Overview

Summary

Medicskin Holdings Ltd. faces profitability challenges with declining revenue and negative net income. High leverage and reduced equity increase financial risks. Strong cash flow management provides some resilience, but strategic focus on improving profitability and managing leverage is critical.

Income Statement

Medicskin Holdings Ltd. shows a mixed performance in its income statement. The gross profit margin has declined from 80.2% in 2022 to 50.7% in 2025, indicating increased cost pressures. The net profit margin is negative for the past three years, reflecting ongoing challenges in achieving profitability. Revenue has decreased by 8.2% from 2024 to 2025, highlighting a potential concern in growth. Despite these challenges, the company has improved its EBITDA margin from 13.8% in 2023 to 13.9% in 2025, showing some operational efficiency improvements.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 5.44 in 2025, indicating significant leverage which poses a financial risk. Stockholders' equity has decreased substantially over the years, reflecting potential financial instability. The equity ratio has also diminished to 7.3% in 2025, suggesting limited financial cushion. Return on equity is not applicable due to negative net income. These factors collectively suggest a need for careful management of financial leverage and equity to ensure long-term stability.

Cash Flow

The cash flow statement shows resilience with a strong free cash flow to net income ratio, despite negative net income, indicating efficient cash management. Operating cash flow has increased to HKD 9.13 million in 2025, supporting liquidity. However, the free cash flow has shown a marginal decrease from the previous year, and capital expenditures have been managed to support cash flow effectively. Overall, the cash flow position remains a relative strength for Medicskin Holdings Ltd.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	45.11M	49.13M	45.54M	49.15M	41.71M
Gross Profit	22.87M	39.39M	36.68M	42.14M	34.40M
EBITDA	6.29M	6.78M	6.40M	14.55M	11.62M
Net Income	-3.38M	-3.05M	-2.98M	3.92M	953.00K
Balance Sheet
Total Assets	57.44M	40.06M	46.37M	56.67M	58.84M
Cash, Cash Equivalents and Short-Term Investments	17.34M	6.93M	6.37M	15.47M	30.33M
Total Debt	22.79M	5.76M	11.93M	18.67M	6.42M
Total Liabilities	53.25M	32.48M	35.21M	42.49M	38.85M
Stockholders Equity	4.20M	10.95M	14.47M	17.43M	23.45M
Cash Flow
Free Cash Flow	8.29M	9.12M	946.00K	2.33M	6.84M
Operating Cash Flow	9.13M	10.52M	3.25M	4.29M	9.15M
Investing Cash Flow	-191.00K	-1.40M	-5.67M	-1.82M	-1.65M
Financing Cash Flow	1.48M	-7.21M	-6.74M	-17.94M	-21.03M

Medicskin Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8307, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.17, and above the 200-day MA of 0.17, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.91 is Neutral, neither overbought nor oversold. The STOCH value of 72.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8307.

Medicskin Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8307	60 Neutral	HK$73.79M	―	-44.60%	―	-8.20%	-10.39%
Sector *	60 Neutral	HK$17.01B	5.40	-7.44%	3.26%	11.55%	-28.15%
8357	60 Neutral	HK$98.59M	―	-1.41%	―	-13.38%	78.75%
8143	51 Neutral	HK$138.66M	―	-18.22%	―	-56.16%	62.50%
8161	47 Neutral	HK$18.72M	2.35	105.83%	―	5.73%	75.18%
8437	44 Neutral	HK$10.46M	―		―	59.11%	48.09%
2135	42 Neutral	HK$63.51M	―	-48.87%	―	3.14%	-57.92%